Loading organizations...
Loading organizations...
Trapelo Health is a technology company.
Trapelo Health provides an interoperable decision-support platform designed for precision oncology. This technology assists oncologists, testing laboratories, and payers by informing testing and treatment decisions, thereby streamlining clinical workflows and the prior authorization process. The platform integrates evidence-based insights to align stakeholders, ensuring patients receive appropriate, evidence-supported options efficiently.
The company was founded in 2009 by Jerry Callahan and Kevin McCurren, originally operating as Intervention Insights. Their initial work leveraged software developed under license from the Van Andel Institute, aiming to translate complex genomic research into practical applications for personalized cancer care. This foundation allowed them to build a system that connects diverse medical entities to improve treatment strategies.
Trapelo Health's platform serves a broad base of users, including cancer centers, testing labs, and health plans, by standardizing value-based precision medicine and driving enhanced reimbursement. The company’s long-term vision centers on overcoming the complexities of precision medicine to give cancer patients the best chance at optimal outcomes, ultimately transforming how advanced cancer therapies are accessed and utilized.
Trapelo Health has raised $10.0M across 2 funding rounds.
Trapelo Health has raised $10.0M in total across 2 funding rounds.
Trapelo Health is a health technology company that developed an interoperable, decision-support platform for precision oncology, enabling oncologists, labs, payers, and pharma to align on evidence-based testing, treatment, and clinical trials for cancer patients.[1][2][3] The platform streamlines clinical workflows, prior authorizations, and reimbursement by curating real-time data from national guidelines, helping providers select appropriate biomarkers, panels, and labs while improving patient access to therapies when time is critical.[2][4][7] It serves cancer centers (standardizing testing), testing labs (enhancing reimbursement), health plans (identifying reimbursable options), and pharma (matching patients to trials), addressing the complexities of rapidly evolving cancer care science, technology, and economics to prioritize patient outcomes.[1][2]
Founded from personal motivations tied to cancer's impact, Trapelo's growth included key partnerships like Texas Oncology and Superior HealthPlan in 2022, culminating in its acquisition by NeoGenomics Bioinformatics, Inc. for $65 million, integrating it into a major oncology lab network.[4][6]
Trapelo Health emerged from nearly a decade of collaboration driven by the personal stories of its team—almost everyone involved has a connection to a loved one or friend affected by cancer—aiming to tackle the accelerating changes in next-generation cancer care.[1][7] Led by Clynt Taylor as president and CEO, the company positioned itself as a pioneer in precision medicine support, with Taylor highlighting visions of multi-stakeholder collaborations to boost patient access.[1][4][6]
Early traction built through partnerships, such as with Concert Genetics to advance molecular oncology decision support and the landmark 2022 launch with Texas Oncology and Superior HealthPlan, which embedded Trapelo into workflows for real-time guideline alignment.[4][5] This paved the way for its 2023 acquisition by NeoGenomics, a strategic fit that accelerated scaling within a global oncology testing leader.[6][7]
Trapelo stands out in precision oncology through these key strengths:
Trapelo rides the precision medicine wave in oncology, where genomic advancements and value-based care demand rapid alignment amid exploding treatment costs and complexities.[2][7] Its timing aligns with post-2020 shifts toward interoperable health tech, enabling faster patient access to therapies amid FDA approvals (e.g., via partners like US Oncology Research) and payer pressures for evidence-based reimbursement.[4][6]
Market forces like rising cancer incidence, biomarker-driven therapies, and trial enrollment challenges favor Trapelo's model, influencing the ecosystem by standardizing workflows and fostering collaborations that scale precision oncology beyond silos.[1][2][6] Now under NeoGenomics, it amplifies lab-physician-payer networks, contributing to broader adoption of molecular insights in routine care.[6][7]
With its NeoGenomics integration, Trapelo is poised to expand globally across NeoGenomics' labs (U.S., Europe, Asia), enhancing its platform's reach in comprehensive oncology testing and trial matching.[6] Trends like AI-augmented genomics, expanded clinical trials, and payer mandates for value-based precision will propel it, potentially evolving into a dominant backbone for oncology decision-making.
As the result of decade-long collaboration born from personal stakes in cancer battles, Trapelo exemplifies how targeted tech can turn rapid scientific change into faster, fairer patient wins—now supercharged for even greater impact.[1][6]
Trapelo Health has raised $10.0M in total across 2 funding rounds.
Trapelo Health's investors include Beringea, Koleman Karleski, Hopen Life Science Ventures, Michigan Accelerator Fund.
Trapelo Health has raised $10.0M across 2 funding rounds. Most recently, it raised $3.0M Venture Round in July 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2013 | $3.0M Venture Round | Beringea | |
| Jul 1, 2011 | $7.0M Series B | Beringea, Koleman Karleski | Hopen Life Science Ventures, Michigan Accelerator Fund |